CN104822379B - 用于免疫调节的沙奎那韦‑no - Google Patents

用于免疫调节的沙奎那韦‑no Download PDF

Info

Publication number
CN104822379B
CN104822379B CN201380060071.4A CN201380060071A CN104822379B CN 104822379 B CN104822379 B CN 104822379B CN 201380060071 A CN201380060071 A CN 201380060071A CN 104822379 B CN104822379 B CN 104822379B
Authority
CN
China
Prior art keywords
saq
disease
cells
saquinavir
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380060071.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822379A (zh
Inventor
F·尼科莱蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angke Nuokesi Co Ltd
Original Assignee
Angke Nuokesi Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angke Nuokesi Co Ltd filed Critical Angke Nuokesi Co Ltd
Publication of CN104822379A publication Critical patent/CN104822379A/zh
Application granted granted Critical
Publication of CN104822379B publication Critical patent/CN104822379B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380060071.4A 2012-11-20 2013-11-20 用于免疫调节的沙奎那韦‑no Expired - Fee Related CN104822379B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728330P 2012-11-20 2012-11-20
US61/728,330 2012-11-20
PCT/EP2013/074264 WO2014079868A1 (en) 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation

Publications (2)

Publication Number Publication Date
CN104822379A CN104822379A (zh) 2015-08-05
CN104822379B true CN104822379B (zh) 2017-08-25

Family

ID=49759262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380060071.4A Expired - Fee Related CN104822379B (zh) 2012-11-20 2013-11-20 用于免疫调节的沙奎那韦‑no

Country Status (11)

Country Link
US (1) US20150283127A1 (https=)
EP (1) EP2922545B1 (https=)
JP (1) JP6283680B2 (https=)
KR (1) KR20150084862A (https=)
CN (1) CN104822379B (https=)
AU (1) AU2013349804A1 (https=)
BR (1) BR112015011299A2 (https=)
CA (1) CA2891771A1 (https=)
IL (1) IL238866A0 (https=)
MX (1) MX2015006249A (https=)
WO (1) WO2014079868A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127858A (zh) * 2014-07-26 2014-11-05 滨州医学院 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082207A1 (en) * 1998-06-11 2003-05-01 Patrice Andre Method of using HIV protease inhibiting compounds
CN102131501A (zh) * 2008-08-01 2011-07-20 加尼尔免疫治疗公司 No修饰的蛋白酶抑制剂的抗肿瘤性能

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063816A1 (en) * 1998-06-09 1999-12-16 Embro William J Method and composition for the treatment of epidermal irritations and infections
WO2003051361A1 (en) * 2001-12-14 2003-06-26 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082207A1 (en) * 1998-06-11 2003-05-01 Patrice Andre Method of using HIV protease inhibiting compounds
CN102131501A (zh) * 2008-08-01 2011-07-20 加尼尔免疫治疗公司 No修饰的蛋白酶抑制剂的抗肿瘤性能

Also Published As

Publication number Publication date
EP2922545B1 (en) 2016-09-21
WO2014079868A1 (en) 2014-05-30
CA2891771A1 (en) 2014-05-30
IL238866A0 (en) 2015-06-30
EP2922545A1 (en) 2015-09-30
JP2015537023A (ja) 2015-12-24
BR112015011299A2 (pt) 2017-07-11
HK1212895A1 (zh) 2016-06-24
JP6283680B2 (ja) 2018-02-21
AU2013349804A1 (en) 2015-06-04
KR20150084862A (ko) 2015-07-22
MX2015006249A (es) 2015-12-03
US20150283127A1 (en) 2015-10-08
CN104822379A (zh) 2015-08-05

Similar Documents

Publication Publication Date Title
Saroj et al. An overview on immunomodulation
Córdova et al. Oleanolic acid controls allergic and inflammatory responses in experimental allergic conjunctivitis
Jager et al. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis
Gao et al. Artemisinins: Promising drug candidates for the treatment of autoimmune diseases
WO2012056344A1 (es) Uso de una composición en base a espironolactona, que presenta una acción inhibitoria de la activación de linfocitos t útil para prevenir y/o tratar esclerosis múltiple
Bodar et al. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra)
Shao et al. Histone deacetylase 11 inhibits interleukin 10 in B cells of subjects with allergic rhinitis
Petković et al. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis
CN104822379B (zh) 用于免疫调节的沙奎那韦‑no
Yamaki et al. Effect of the nonsteroidal anti-inflammatory drug indomethacin on Th1 and Th2 immune responses in mice
AU615745B2 (en) Method of effecting immunosuppression
Li et al. Curcumin improves experimentally induced colitis in mice by regulating follicular helper T cells and follicular regulatory T cells by inhibiting interleukin-21.
Sun et al. The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice
TWI320714B (en) Plant extracts for the treatment of rheumatoid arthritis
Majoor et al. Corneal autoimmunity in Cogan's syndrome? Report of two cases
JP2001501620A (ja) 免疫不全ウイルス感染の治療方法
Zimecki et al. Lactoferrin ameliorates symptoms of experimental encephalomyelitis in Lewis rats
HK1212895B (en) Saquinavir-no for immunomodulation
RU2531945C2 (ru) Средство против передачи вич/спид половым путем
EP3381934A1 (en) Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein
WO1989009229A1 (en) Treatment of hiv viremic patients with thymopentin
Dai et al. Bowman–Birk inhibitor attenuates experimental autoimmune encephalomyelitis by delaying infiltration of inflammatory cells into the CNS
KR20160096804A (ko) 조루증 예방 및 치료용 한약재 조성물
ES2257666T3 (es) Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.
WO2015100150A1 (en) Oral administration of tocilizumab treatment of autoimmune disease

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212895

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1212895

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170825